FDA frames non‑animal evidence
The FDA published a draft guidance for validating non‑animal testing methods, setting out scientific standards that explain what counts as credible evidence for alternatives to animal studies. The document describes expectations for method validation and suggests regulators will accept human‑relevant and computational approaches where the evidence package meets the agency’s criteria. (Applied Clinical Trials)
The Food and Drug Administration has put in writing what drugmakers must show if they want lab-grown tissues, computer models, or other non-animal tests to count in a drug filing. (fda.gov) The agency released the draft guidance on March 18, 2026 through its Center for Drug Evaluation and Research, then published it in the Federal Register on March 19 with a public comment deadline of May 18, 2026. (fda.gov) (federalregister.gov) These methods are called new approach methodologies, or new tools that test drugs in cells, organ-like lab systems, chemistry assays, software simulations, or lower-order animals such as zebrafish and C. elegans instead of relying only on mice, rats, or monkeys. (fda.gov) (congress.gov) The draft does not approve any single technology. It tells sponsors to define a method’s exact job, show that it reflects human biology, document how it performs, and prove it is fit for the decision the Food and Drug Administration is being asked to make. (federalregister.gov) (raps.org) In plain terms, the Food and Drug Administration is saying the question is no longer whether a package includes animals. The question is whether the evidence is reliable enough to support a safety or development decision. (fda.gov) (federalregister.gov) That shift has been building since Congress passed the Food and Drug Administration Modernization Act 2.0 in 2022, replacing statutory references to “preclinical tests (including tests on animals)” with “nonclinical tests” and explicitly listing in vitro, in silico, and other human biology-based methods. (congress.gov) The agency accelerated the effort on April 10, 2025, when it said it would begin phasing out animal testing requirements for monoclonal antibodies and other drugs and encouraged sponsors to include non-animal data in investigational new drug applications immediately. (fda.gov) Food and Drug Administration officials have argued that animal studies often miss human safety and efficacy problems that appear later, while organoids, organs-on-chips, and computer models can sometimes give a closer readout of how a human body will respond. (fda.gov 1) (fda.gov 2) The draft guidance is narrower than a blanket ban on animal studies. The Federal Register notice says animal toxicity studies remain a critical way to identify risks, and the document is meant to give broad validation principles rather than replace every existing test overnight. (federalregister.gov) What happens next is procedural but important: companies, researchers, and advocacy groups have until May 18 to comment, and the final version will show how quickly the Food and Drug Administration is willing to turn its non-animal push into review practice. (federalregister.gov)
